BlackRock Fund Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BlackRock Fund Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$7K	Buy	10 +3	+43%	+$3.21K	﹤0.01%	4016
2016 Q3	$7K	Sell	7 -85	-92%	-$74.1K	﹤0.01%	4016
2016 Q2	$71K	Sell	92 -19	-17%	-$17.8K	﹤0.01%	3748
2016 Q1	$77K	Sell	111 -9	-8%	-$7.8K	﹤0.01%	3724
2015 Q4	$117K	Buy	120 +3	+3%	+$3.96K	﹤0.01%	3700
2015 Q3	$124K	Sell	117 -3	-3%	-$4.38K	﹤0.01%	3646
2015 Q2	$247K	Buy	120 +65	+118%	+$92.4K	﹤0.01%	3444
2015 Q1	$52K	Sell	55 -3	-5%	-$2.98K	﹤0.01%	3695
2014 Q4	$60K	Buy	58 +4	+7%	+$3.57K	﹤0.01%	3662
2014 Q3	$56K	Sell	54 -4	-7%	-$5.9K	﹤0.01%	3699
2014 Q2	$113K	Sell	58 -464	-89%	-$918K	﹤0.01%	3603
2014 Q1	$1.12M	Buy	522 +15	+3%	+$37.4K	﹤0.01%	3186
2013 Q4	$1.17M	Sell	507 -514	-50%	-$1.18M	﹤0.01%	3184
2013 Q3	$2.9M	Buy	1,021 +137	+15%	+$682K	﹤0.01%	3057
2013 Q2	$8.16M	Buy	+884	New	+$6.81M	﹤0.01%	2379

Other funds holding ONCT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FHA

First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DAM

Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

KLI

Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

BlackRock Fund Advisors's ONCT Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Oncternal Therapeutics, Inc. Common Stock (ONCT) stake by 43% in Q4 2016, buying an estimated $3.21K and bringing the position to 10 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

BlackRock Fund Advisors first reported a position in ONCT in Q2 2013 and has held it in 15 quarters since. The position peaked at $8.16M in Q2 2013. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

BlackRock Fund Advisors held 10 shares of Oncternal Therapeutics, Inc. Common Stock worth $7K as of Q4 2016.
BlackRock Fund Advisors bought 3 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $3.21K.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4016 holding.
BlackRock Fund Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $8.16M in Q2 2013.
21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.